QS Investors’s Heron Therapeutics HRTX Stock Holding History

QS Investors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,630	Closed	-$65K	–	1652
2019 Q1	$65K	Hold	2,630	–	–	﹤0.01%	1473
2018 Q4	$69K	Hold	2,630	–	–	﹤0.01%	1406
2018 Q3	$83K	Hold	2,630	–	–	﹤0.01%	1426
2018 Q2	$102K	Buy	+2,630	New	+$83.7K	﹤0.01%	1406

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

QS Investors's HRTX Position: Q2 2019 in Review

QS Investors sold out of Heron Therapeutics (HRTX) in Q2 2019, closing a stake of 2,630 shares — an estimated $65K sold.

QS Investors first reported a position in HRTX in Q2 2018 and held it in 4 quarters. The position peaked at $102K in Q2 2018. 176 funds tracked by Wall St. Rank hold HRTX as of Q2 2019.

QS Investors reported no remaining Heron Therapeutics position as of Q2 2019 after selling out during the quarter.
QS Investors sold 2,630 Heron Therapeutics shares in Q2 2019, an estimated $65K.
QS Investors first reported a position in Heron Therapeutics in Q2 2018 and held it in 4 quarters.
QS Investors's Heron Therapeutics position peaked at $102K in Q2 2018.
176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2019.

Based on QS Investors's 13F filing for Q2 2019, filed 14 Aug 2019.